iris/neoplasms

The link is saved to the clipboard

Choose sort type

Page 1 from 65 results

Observational Study of Iris Tumors

Only registered users can translate articles

NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer

Only registered users can translate articles

- At the time of initial diagnosis of pancreatic cancer, resectable pancreatic cancer is around 20%, locally-advanced pancreatic cancer is around 25-30%, and the remaining is metastatic pancreatic cancer. - In metastatic pancreatic cancer, Gemcitabine/Abraxane or FOLFIRINOX

First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI

Only registered users can translate articles

Pancreatic cancer (PC) is the seventh cause from cancer and the fifth cause from cancer-related death in Europe. Nearly as many deaths occur from PC than the number of new cases diagnosed each year, reflecting the poor prognosis typically associated with this disease. PC is insidious in onset and is

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

Only registered users can translate articles

PRIMARY OBJECTIVES: I. Determine the recommended phase II dose for the combination of TAS-102 and nanoliposomal irinotecan (nanoliposomal [nal]-IRI). (Phase I) II. Evaluate the activity of the combination of TAS102 and nal-IRI in previously treated patients with metastatic colorectal cancer and

Second Line Treatment With Nal-IRI and S1 in Pancreatic Cancer

Only registered users can translate articles

The 5-year survival of patients with pancreatic cancer is less than 5%. Despite improvements over the past years with the introduction of FOLFIRINOX (5-fluorouracil, irinotecan, oxaliplatin and leucovorin) and gemcitabine and nab-paclitaxel, the vast majority will have disease recurrence or

Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)

Only registered users can translate articles

This study has two cohorts. In Cohort A, patients who met the inclusion criteria(ER，PR<10%, T≤2cm or ER,PR ≥10% 1cm＜T≤2cm）would be given capecitabine for 6 cycles with standard trastuzumab for 1 year, in which HR+ patients would be given endocrine therapy for 5 years. In Cohort B, patients who met

IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer

Only registered users can translate articles

A multicenter randomized open-label controlled phase III study is conducted in patients with inoperable advanced or metastatic colorectal cancer who receive no previous chemotherapy. Usefulness of IRIS and mFOLFOX6 regimens as the 1st-line therapy for colorectal cancer is evaluated in PFS, MST,

Trial of FOLF(HA)Iri With Cetuximab in mCRC

Only registered users can translate articles

Trial of FOLF(HA)Iri Versus FOLFIRI in mCRC

Only registered users can translate articles

Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer

Only registered users can translate articles

This study is a multicenter, open-label, randomized, phase II study comparing the efficacy and safety between fluorouracil/folinic acid plus liposomal irinotecan and fluoruracil/folinic acid monotherapy in patients with metastatic biliary tract cancer which progressed on 1st line

Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma.

Only registered users can translate articles

- Number of patients : Total 24 patients (6-12 patients in phase 1 part and 12 patients in expansion cohort ) - Treatment : - Vactosertib* 100-300 mg bid for 5 days - Liposomal Irinotecan (Onivyde) 70mg/m2 on D1 - LV 200mg/m2 IV bolus on D1 - 5-FU 2400mg/m2 CIV over 46 hours on D1 - Vactosertib will

Phase II Study of Oral S-1 Plus Irinotecan (IRIS) in Patients With Advanced Colorectal Cancer

Only registered users can translate articles

A multicenter Open-label, single-arm, phase II clinical trial is conducted on patients with histological stage IV colorectal cancer given irinotecan plus S-1. The usefulness of this regimens as 1st line therapy for colorectal cancer was evaluated by the disease-free survival rate (DFR), overall

Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.

Only registered users can translate articles

Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer

Only registered users can translate articles

Part 1: Patients will be enrolled to determine the maximum tolerated dose, safety and tolerability of MM-151 + nal-IRI + 5-FU + LV in patients with mCRC that are RAS/RAF wild-type. Part 2: Patients will be enrolled at the maximum tolerated dose of MM-151 in combination with nal-IRI + 5-FU + LV to

Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors

Only registered users can translate articles

Primary Objectives - to determine the maximum tolerated dose (MTD) of nal-IRI (ONIVYDE®) in combination with TAS-102 (LONSURF®) - to evaluate the toxicity profile of the combination therapy Secondary Objectives - to evaluate the preliminary efficacy of the combination therapy of nal-IRI (ONIVYDE®)

Join our facebook page

Herbal & Natural Medicine

The most complete medicinal herbs database backed by science

Works in 55 languages
Herbal cures backed by science
Herbs recognition by image
Interactive GPS map - tag herbs on location (coming soon)
Read scientific publications related to your search
Search medicinal herbs by their effects
Organize your interests and stay up do date with the news research, clinical trials and patents

Type a symptom or a disease and read about herbs that might help, type a herb and see diseases and symptoms it is used against.
*All information is based on published scientific research